← Back to Search

Active ropivacaine 0.3% erector spinae plane perineural administration for Trauma

Phase 4

Waitlist Available

Led By Brian M Ilfeld, MD, MS

Research Sponsored by University of California, San Diego

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up months 0.5, 1, 1.5, 2, 3, 6, 12 following procedure

Awards & highlights

Study Summary

This trial is investigating whether a continuous ESPB added to a single-injection ESPB can improve the maximum inspired volume and decrease pain in patients with traumatic rib fractures.

Eligible Conditions

Trauma
Rib Fractures
Anesthesia
Local Anesthesia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ months 0.5, 1, 1.5, 2, 3, 6, 12 following procedure

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~months 0.5, 1, 1.5, 2, 3, 6, 12 following procedure

This trial's timeline: 3 weeks for screening, Varies for treatment, and months 0.5, 1, 1.5, 2, 3, 6, 12 following procedure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Secondary outcome measures

AVERAGE Rib Fracture Pain in Previous 24 Hours

Brief Pain Inventory (Short Form, Interference Subscale)

CURRENT Rib Fracture Pain in Previous 24 Hours

+7 more

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Active TreatmentExperimental Treatment1 Intervention

This group will receive a single injection nerve block of ropivacaine 0.5% (20 mL) followed by an infusion/boluses of ropivacaine 0.3% (continuous block)

Group II: PlaceboPlacebo Group1 Intervention

This group will receive a single injection nerve block of ropivacaine 0.5% (20 mL) followed by an infusion/boluses of normal saline

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of California, San DiegoLead Sponsor

1,120 Previous Clinical Trials

1,521,631 Total Patients Enrolled

Brian M Ilfeld, MD, MSPrincipal InvestigatorUniversity of California, San Diego

19 Previous Clinical Trials

1,537 Total Patients Enrolled

John J Finneran IV, MDStudy DirectorUniversity of California, San Diego

1 Previous Clinical Trials

70 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA sanctioned Active ropivacaine 0.3% erector spinae plane perineural administration?

"The safety of Active ropivacaine 0.3% erector spinae plane perineural administration was assessed as a 3 on our scale due to the approval status of this treatment, being within Phase 4 trials."

Answered by AI

Is recruitment currently ongoing for this experiment?

"Affirmative, clinicaltrials.gov attests that this scientific experimentation is actively searching for participants. The first posting of the trial was on May 23rd 2021 with its latest update occurring June 4th 2022; 20 patients need to be enrolled from a single location."

Answered by AI

How many participants are expected to join this research initiative?

"Affirmative. Clinicaltrials.gov verifies that this medical trial, which was first published on May 23rd 2021, is now recruiting participants. Approximately 20 people are required from 1 site in order to complete the study."

Answered by AI

To what afflictions has Active ropivacaine 0.3% erector spinae plane perineural administration been found useful?

"Active ropivacaine 0.3% administered through the erector spinae plane is a proven technique to provide anesthetics during surgical procedures, labour, and other anesthesia scenarios."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Continuous Erector Spinae Plane Blocks for Rib Fractures

Brian M. Ilfeld, MD, MS 2021. "Continuous Erector Spinae Plane Blocks for Rib Fractures". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04558281.